Reborna Biosciences, Inc. (Kanagawa, Japan; hereinafter, “Reborna”) announced that it has entered into a research collaboration with Biogen (Mass., United States; hereinafter, “Biogen”; Nasdaq: BIIB) in the field of central nervous system diseases.

Under the terms of the agreement, Reborna will receive an upfront payment from Biogen. Upon exercise of its option by Biogen, Reborna will grant Biogen a global license to develop, manufacture and commercialize a yet-to-be-named compound. Reborna is eligible for development and commercial milestones as well as royalties based on commercial sales.

As one of the world’s first global biotechnology companies, Biogen continues to pursue therapies for individuals living with serious neurological and neurodegenerative diseases. This collaboration may have the potential to launch a new and more efficacious treatment that can be accessible to broader patient populations as quickly as possible.

“Biogen is a leading company in the field of neurological diseases, and we are very pleased that our drug discovery technology has been well-received by the organization. We hope to continue this collaboration with Biogen with the goal of potentially bringing medicines to people living with central nervous system disease,” said Koji Fuji, Ph.D., Chief Executive Officer at Reborna.

About Reborna Biosciences, Inc.
Reborna is engaged in drug discovery research for oral drugs that show disease modifying effects through normalizing RNA function by using small molecule drugs with high affinity for RNA. We will contribute to society by providing new drugs that enable patients suffering from rare genetic diseases and their families to feel that they have been reborn.
For more information, please visit http://rebornabiosciences.com.